Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8α+ dendritic cells and reduces experimental acute graft-versus-host disease
Teshima T, Reddy P, Lowler K, KuKuruga M, Liu C, Cooke K, Ferrara J. Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8α+ dendritic cells and reduces experimental acute graft-versus-host disease. Blood 2002, 99: 1825-1832. PMID: 11861301, DOI: 10.1182/blood.v99.5.1825.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdjuvants, ImmunologicAnimalsBone Marrow TransplantationCD8 AntigensCell DivisionCoculture TechniquesDendritic CellsDisease Models, AnimalFemaleGraft vs Host DiseaseLymphocyte ActivationMembrane ProteinsMiceMice, Inbred C57BLSurvival RateT-LymphocytesTransplantation, HomologousConceptsDendritic cellsT cell responsesAcute graftHost diseaseDonor T-cell responsesAllogeneic bone marrow transplantationAllogeneic T-cell responsesAllogeneic bone marrow transplantExperimental acute graftHost dendritic cellsPoor stimulatory capacityNormal dendritic cellsAllogeneic T cellsBone marrow transplantationTreatment of miceBone marrow transplantFL treatmentAcute GVHDGVHD mortalityDC subsetsAllogeneic lymphocytesDC numbersMarrow transplantationLigand therapyMarrow transplant